ESMO 2017: 3-week dosing schedule for paclitaxel is suitable as first-line treatment for European women with ovarian cancer

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Caucasian women with ovarian cancer can be treated with the standard 3-week dosing schedule for paclitaxel according to ICON8 phase 3 study presented at ESMO 2017.

Why this matters

  • The study, conducted by the MRC Clinical Trials Unit at UCL, contradicts the results of the J...